Treatment of hepatitis C monoinfection in adults - Dutch national guidelines

Netherlands Journal of Medicine

Volumn 71, Issue 7, 2013, Pages 377-385

  Lamers, M H ^a   Broekman, M M T J ^a   Boucher, C A ^b   Brouwer, J T ^c   Burger, D M ^a   van Hoek, B ^d   Hoepelman, A I M ^e   de Knegt, R J ^b   Reesink, H W ^f   Drenth, J P H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c REINIER DE GRAAF HOSPITAL   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Boceprevir; Guidelines; Hepatitis C; Pegylated interferon; Protease inhibitor; Ribavirin; Telaprevir

Indexed keywords

BOCEPREVIR; CYTOCHROME P450 3A; MULTIDRUG RESISTANCE PROTEIN; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; RIBAVIRIN; SIMVASTATIN; TELAPREVIR;

AGITATION; ANEMIA; ANTIVIRAL RESISTANCE; ARTICLE; CONCENTRATION LOSS; DEPRESSION; DRUG DOSE REDUCTION; DYSGEUSIA; ELASTOGRAPHY; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; INSOMNIA; IRRITABILITY; LIVER BIOPSY; LIVER FIBROSIS; MENTAL INSTABILITY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RASH; SIDE EFFECT; STAGING; THROMBOCYTOPENIA; TREATMENT RESPONSE; ULTRASOUND; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DRUG INTERACTIONS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; NETHERLANDS; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84884189106     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (99)

1. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl 1:74-81.
2. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-206.
3. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-16.
4. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1014-24.
5. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection. New Engl J Med. 2011;364:1207-17.
6. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for Retreatment of HCV Infection. New Engl J Med. 2011;364:2417-28.
7. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433-44.
8. Ramachandran P, Fraser A, Agarwal K, et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther. 2012;35:647-62.
9. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245-64.
10. de Bruijne J, Buster EH, Gelderblom HC, et al. Treatment of chronic hepatitis C virus infection-Dutch national guidelines. Neth J Med. 2008;66:311-22.
11. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41-52.
12. Seeff LB. The history of the "natural history" of hepatitis C (1968-2009). Liver Int. 2009;29 Suppl 1:89-99.
13. Williams MJ, Lang-Lenton M. Progression of initially mild hepatic fibrosis in patients with chronic hepatitis C infection. J Viral Hepat. 2011;18:17-22.
14. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol. 2001;34:730-9.
15. Anderson KB, Guest JL, Rimland D. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clin Infect Dis. 2004;39:1507-13.
16. Lee MH, Yang HI, Lu SN, et al. Chronic Hepatitis C Virus Infection Increases Mortality From Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study. J Infect Dis. 2012;206:469-77.
17. Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis. 2007;39:2-17.
18. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9:509-16 e1.
19. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8:280-8.
20. van Soest H, Boland GJ, van Erpecum KJ. Hepatitis C: changing genotype distribution with important implications for patient management. Neth J Med. 2006;64:96-9.
21. de Vries MJ, te Rijdt B, van Nieuwkerk CM. Genotype distribution amongst hepatitis C patients in The Netherlands. Neth J Med. 2006;64:109-13.
22. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580-93.
23. Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology. 2010;51:1176-84.
24. Mondelli MU, Cerino A, Cividini A. Acute hepatitis C: diagnosis and management. J Hepatol. 2005;42 Suppl(1):S108-14.
25. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125:80-8.
26. Deterding K, Grüner, N., Buggisch, P, et al. Early versus delayed treatment of acute hepatitis C: final results of the randomized controlled german hep-net acute HCV-III study. J Hepatol. 2012;56:S21.
27. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558-67.
28. Slavenburg S, Verduyn-Lunel FM, Hermsen JT, Melchers WJ, te Morsche RH, Drenth JP. Prevalence of hepatitis C in the general population in the Netherlands. Neth J Med. 2008;66:13-7.
29. Vriend HJ, Op de Coul EL, van de Laar TJ, Urbanus AT, van der Klis FR, Boot HJ. Hepatitis C virus seroprevalence in The Netherlands. Eur J Public Health. 2012.
30. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol. 2008;48:148-62.
31. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48:418-31.
32. http://www.mdl.nl/hepatitis_behandelcentra / www.NIV.nl.
33. Reiss G, Keeffe EB. Review article: hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther. 2004;19:715-27.
34. Bruno S, Shiffman ML, Roberts SK, et al. Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis. Hepatology. 2010;51:388-97.
35. Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol. 2010;53:1013-21.
36. Smith JO, Sterling RK. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther. 2009;30:557-76.
37. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350:2265-71.
38. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
39. Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology. 2003;37:600-9.
40. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol. 2005;43:425-33.
41. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol. 2011;55:69-75.
42. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061-9.
43. Sulkowski MS, Shiffman ML, Afdhal NH, et al. Hepatitis C virus treatmentrelated anemia is associated with higher sustained virologic response rate. Gastroenterology. 2010;139:1602-11.
44. Loustaud-Ratti V, Carrier P, Rousseau A, et al. Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment. Dig Liver Dis. 2011;43:850-5.
45. Thompson AJ, McHutchison JG. Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus? Hepatology. 2012;56:373-81.
46. Poordad F, Bronowicki JP, Gordon SC, et al. Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir. Gastroenterology. 2012. Epub 2012/05/26.
47. Niederau C, Huppe D, Zehnter E, et al. Chronic hepatitis C: treat or wait? Medical decision making in clinical practice. World J Gastroenterol. 2012;18:1339-47.
48. McGowan CE, Fried MW. Barriers to hepatitis C treatment. Liver Int. 2012;32 Suppl 1:151-6.
49. Guideline Hepatocellular Carcinoma (HCC) (in concept). Available at: www.oncoline.nl. Comprehensive Cancer Centre the Netherlands (IKNL). Viewed on [6 November 2012].
50. National Institute for Public Health and Environment: Dutch national guideline needlestick injuries. April 2007.
51. Wiegand J, Deterding K, Cornberg M, Wedemeyer H. Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha. J Antimicrob Chemother. 2008;62:860-5.
52. Arends JE, Lambers FA, van der Meer JT, et al. Treatment of acute hepatitis C virus infection in HIV+ patients: Dutch recommendations for management. Neth J Med. 2011;69:43-9.
53. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS. 2011;25:399-409.
54. Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or-2b to patients with chronic hepatitis C. Gastroenterology. 2011;140:459-68 e1; quiz e14.
55. Flamm SL, Lawitz E, Jacobson I, et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol. 2013;11:81-7 e4; quiz e5.
56. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_ Product_Information/human/002313/WC500115529.pdf. Product information Incivo(r) (telaprevir) tablets.
57. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_ Product_Information/human/002332/WC500109786.pdf. Product information Victrelis(r) (boceprevir) capsules.
58. Cooper CL, Druyts E, Thorlund K, et al. Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis. Therapeutics Clin Risk Manage. 2012;8:105-30.
59. Cure S, Diels J, Gavart S, Bianic F, Jones E. Efficacy of telaprevir and boceprevir in treatment-naive and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis. Curr Med Res Opin. 2012.
60. Aronson SJ, de Bruijne J, Schinkel J, Weegink CJ, van der Valk M, Reesink HW. [New class of medicines for chronic hepatitis C]. Ned Tijdschr Geneeskd. 2012;156(10):A3840. Epub 2012/03/08. Nieuwe klasse medicijnen voor chronische hepatitis C.
61. Reddy KR, Lin F, Zoulim F. Response-guided and-unguided treatment of chronic hepatitis C. Liver Int. 2012;32 Suppl 1:64-73.
62. Liu J, Jadhav PR, Amur S, et al. Response Guided Telaprevir Therapy in Prior Relapsers?: The Role of Bridging Data from Treatment-Naive and Experienced Subjects. Hepatology. 2012. Epub 2012/04/11.
63. Harrington PR, Zeng W, Naeger LK. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology. 2012;55:1048-57.
64. Di Martino V, Richou C, Cervoni JP, et al. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. Hepatology. 2011;54:789-800.
65. Pol S, Roberts SK, Andreone P, et al. Efficacy and safety of telaprevirbased regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the realize phase III study. Hepatology. 2011;54:375A.
66. Mangia A, Mottola L. Treatment of non-genotype 1 hepatitis C virus patients. Curr Gastroenterol Rep. 2012;14:87-93.
67. Hadziyannis SJ, Sette H Jr., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-55.
68. Mangia A, Mottola L. What's new in HCV genotype 2 treatment. Liver Int. 2012;32 Suppl 1:135-40.
69. Manns M, Zeuzem S, Sood A, et al. Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. J Hepatol. 2011;55:554-63.
70. Khattab MA, Ferenci P, Hadziyannis SJ, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol. 2011;54:1250-62.
71. Kamal SM, El Kamary SS, Shardell MD, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology. 2007;46:1732-40.
72. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008;135:451-8.
73. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology. 2006;131:997-1002.
74. Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology. 2007;132:1270-8.
75. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007;132:1767-77.
76. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology. 2010;138:447-62.
77. Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology. 2009;50:1709-18.
78. Burger DM. Drug interactions with anti-HCV-agents. 2012; an update of the table and more information can be found at www.knmp.nl and enter HCV as search term.
79. Burger D, Back D, Buggisch P, et al. Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions. J Hepatol. 2012. Epub 2012/11/10.
80. Garg V, van Heeswijk R, Yang Y, Kauffman R, Smith F, Adda N. The Pharmacokinetic Interaction Between an Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone and the HCV Protease Inhibitor Telaprevir. J Clin Pharmacol. 2011. Epub 2011/11/01.
81. Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol. 2012;11:179-85.
82. Lee JE, van Heeswijk R, Alves K, Smith F, Garg V. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother. 2011;55:4569-74.
83. Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012;55:1620-8.
84. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55:1350-9.
85. Hezode C. Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice. Liver Int. 2012;32 Suppl 1:32-8.
86. Manns MP, Markova AA, Serrano BC, Cornberg M. Phase III results of Boceprevir in treatment naive patients with chronic hepatitis C genotype I. Liver Int. 2012;32 Suppl 1:27-31.
87. Sulkowski MS, Roberts, S., N. Afdhal, P, et al. Ribavirin dose modification in treatment-naive and previously treated patients who received telaprevir combination treatment: no impact on sustained virologic response in phase 3 studies. J Hepatol. 2012;56(Suppl 2):S459-S60.
88. Poordad FF, Lawitz EJ, Reddy KR, et al. A Randomized Trial Comparing Ribavirin Dose Reduction Versus Erythropoietin for Anemia Management in Previously Untreated Patients with Chronic Hepatitis C Receiving Boceprevir Plus Peginterferon/Ribavirin. J Hepatol. 2012;56:S559-S.
89. Lippi G, Franchini M, Favaloro EJ. Thrombotic complications of erythropoiesis-stimulating agents. Semin Thromb Hemost. 2010;36:537-49.
90. Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology. 2010;52:1225-31.
91. Tandon P, Doucette K, Fassbender K, Vandermeer B, Durec T, Dryden DM. Granulocyte colony-stimulating factor for hepatitis C therapy-associated neutropenia: systematic review and economic evaluation. J Viral Hepat. 2011;18:e381-93.
92. Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. J Hepatol. 2010;53:455-9.
93. Picard O, Cacoub P. Dermatological adverse effects during genotype-1 hepatitis C treatment with the protease inhibitors telaprevir and boceprevir. Patient management. Clin Res Hepatol Gastroenterol. 2012. Epub 2012/04/10.
94. Cacoub P, Bourliere M, Lubbe J, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol. 2012;56:455-63.
95. Bonaccorso S, Puzella A, Marino V, et al. Immunotherapy with interferonalpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res. 2001;105:45-55.
96. Sulkowski MS, Cooper C, Hunyady B, Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011;8:212-23.
97. Trapero-Marugan M, Mendoza J, Chaparro M, et al. Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin. World J Gastrolenterol. 2011;17:493-8.
98. Martinot-Peignoux M, Stern C, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology. 2010;51:1122-6.
99. Kobayashi S, Takeda T, Enomoto M, et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Int. 2007;27:186-91.